Line items represent reporting concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 12

-Section 12

-Sentence Column A

+ Details

Name:	invest_InvestmentLineItems
Namespace Prefix:	invest_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Available-for-Sale Securities, Ownership Percentage

+ References

No definition available.

+ Details

Name:	opk_AvailableforSaleSecuritiesOwnershipPercentage
Namespace Prefix:	opk_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name:	us-gaap_GainLossOnSaleOfInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_NeovascMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_CocrystalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_ARNOMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_SevionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=opk_MabVaxTherapeuticsHoldingsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	invest_InvestmentAxis=opk_RxiPharmaceuticalsCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	invest_InvestmentAxis=opk_ChromaDexMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	invest_InvestmentAxis=opk_ARNOMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Acquisitions, Investments, and Licenses - Available for Sale Investments, Sale of Investments and Warrants and Options Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Apr. 30, 2015	Dec. 31, 2014
Investment [Line Items]
Gain (loss) on sale of investments	$ 216	$ 1,274
Other Income
Investment [Line Items]
Gain (loss) on sale of investments		$ 1,300
Neovasc
Investment [Line Items]
Warrants to purchase common shares				1,000,000
Cocrystal
Investment [Line Items]
Warrants to purchase common shares				1,000,000
ARNO
Investment [Line Items]
Warrants to purchase common shares				800,000
Sevion
Investment [Line Items]
Warrants to purchase common shares				100,000
MabVax
Investment [Line Items]
Warrants to purchase common shares			1,666,667	1,700,000
Rxi Pharmaceuticals Corporation
Investment [Line Items]
Ownership percentage	10.00%
ChromaDex
Investment [Line Items]
Ownership percentage	2.00%
ARNO
Investment [Line Items]
Ownership percentage	4.00%